Paratek Pharmaceuticals Presenting New Data from NUZYRA and Investigator-Initiated Research Programs at the European Congress of Clinical Microbiology Infectious Diseases 2023
PRTKDelisted Stock | USD 2.18 0.00 0.00% |
About 56% of Paratek Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Paratek Pharmaceuticals suggests that many traders are alarmed regarding Paratek Pharmaceuticals' prospects. Paratek Pharmaceuticals' investing sentiment shows overall attitude of investors towards Paratek Pharmaceuticals.
Paratek |
BOSTON, April 10, 2023 -- Paratek Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that new data from studies with NUZYRA will be presented at the European Congress of Clinical Microbiology Infectious Diseases . The hybrid
Read at finance.yahoo.com
Paratek Pharmaceuticals Fundamental Analysis
We analyze Paratek Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Paratek Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Paratek Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Paratek Pharmaceuticals is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Paratek Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Paratek Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Paratek Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Paratek Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Paratek Pharmaceuticals Related Equities
IMMP | Immutep | 6.60 | ||||
LYRA | Lyra Therapeutics | 0.48 | ||||
ADAP | Adaptimmune Therapeutics | 0.48 | ||||
HOOK | Hookipa Pharma | 0.41 | ||||
CRVS | Corvus Pharmaceuticals | 1.60 | ||||
JSPR | Jasper Therapeutics | 2.02 | ||||
AFMD | Affimed NV | 2.93 | ||||
EQ | Equillium | 4.11 | ||||
LPTX | Leap Therapeutics | 4.11 | ||||
APTO | Aptose Biosciences | 4.21 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Paratek Stock
If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |